miR-509–5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11
Pathology - Research and Practice · 2023-07 · 247 · 154557
DOI: 10.1016/j.prp.2023.154557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023-07. Verfasst von Mahmoud A Elrebehy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. Electronic address: mahmoud.elrebeihy…. Hauptthemen laut MEDLINE: Ferroptosis, Colorectal Neoplasms, MicroRNAs. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 91 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND/AIM: Colorectal cancer (CRC), is characterized by aberrant microRNA (miRNA) expression during their development and progression. Recently, miR-509-5p's role as a regulator of several malignancies has been highlighted. Its function in CRC, however, is exposed. This research aimed to determine the relative abundance of miR-509-5p and its biological function in colorectal cancer. METHODS: The expression of miR-509-5p in CRC cell lines and tissues, as well as neighboring normal tissues, was evaluated using real-time quantitative polymerase chain reaction (RT-PCR). 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl-2 H-tetrazolium bromide (MTT) was used to assess cell viability. The association between miR-509-5p and its predicted target in CRC cells was analyzed using bioinformatics tools. The levels of Solute carrier family seven number 11 (SLC7A11) were assessed using enzyme-linked immunosorbent assay (ELISA), while malondialdehyde (MDA) and iron content levels were determined colorimetrically. RESULTS: Compared to adjacent normal tissue and normal colorectal cell, there was a significant reduction in miR-509-5p expression in both CRC tissues and cells. miR-509-5p upregulation inhibited Caco-2 cell viability. SLC7A11 was predicted to be the cellular target of miR-509-5p. Interestingly, miR-509-5p's overexpression suppressed both mRNA and protein levels of SLC7A11, whereas its downregulation boosted SLC7A11 gene expression. Finally, overexpressing miR-509-5p resulted in increased MDA and iron levels. CONCLUSION: Our results demonstrate that miR-509-5p has CRC tumor suppressor functions through controlling the expression of SLC7A11 and promotion of ferroptosis providing a new therapeutic target for the treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt. Electronic address: mahmoud.elrebeihy@buc.edu.eg.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, Cairo 11231, Egypt; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Heliopolis University, Cairo 117…
- Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City 11231, Cairo, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Badr University in Cairo (BUC), Badr City, Cairo 11829, Egypt; Biochemistry and Molecular Biology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City 1…
Zitieren
APA
Elrebehy, M. A., Abdelghany, T. M., Elshafey, M. M., Gomaa, M. H., & Doghish, A. S. (2023). miR-509–5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11. Pathology - Research and Practice, 247, 154557. https://doi.org/10.1016/j.prp.2023.154557
Vancouver
Elrebehy MA, Abdelghany TM, Elshafey MM, Gomaa MH, Doghish AS. miR-509–5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11. Pathology - Research and Practice. 2023;247:154557. doi:10.1016/j.prp.2023.154557
BibTeX
@article{Elrebehy2023,
author = {Elrebehy, Mahmoud A and Abdelghany, Tamer M and Elshafey, Mostafa M and Gomaa, Maher H and Doghish, Ahmed S},
title = {miR-509–5p promotes colorectal cancer cell ferroptosis by targeting SLC7A11},
journal = {Pathology - Research and Practice},
year = {2023},
volume = {247},
pages = {154557},
doi = {10.1016/j.prp.2023.154557}
}
EUVIMED